Neuralstem, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

CUR 0.350 -0.240 (-40.67%)
price chart
Featured Biotech Stock: Neuralstem, Inc. (NASDAQ:CUR)
Share of Neuralstem, Inc. (NASDAQ:CUR) traded on -40.04 percent below secure line at 1:29PM EDT in order to take the company's stock at the price of $0.354.
Neuralstem, Inc. (CUR) Analyst Review  Risers & Fallers
Neuralstem initiates equity offering; shares down 15% after hours  Seeking Alpha
Neuralstem Inc (CUR) Drops 40.67% on May 03
Neuralstem Inc (CUR) was one of the Russell 2000's biggest losers for Tuesday May 03 as the stock slid 40.67% to $0.35, a loss of $-0.2399 per share.
Tuesday Pre-Market Insights: Northwest Biotherapeutics, Inc (NWBO), Neuralstem ...
Neuralstem, Inc. (NASDAQ:CUR) is falling over 37% in pre-market trading after the company announced a proposed public offering of common stock of 20,000 shares at $0.40 per share.
Stocks Hitting 52-Week Lows
Neuralstem, Inc. (NASDAQ: CUR) shares fell 39.46 percent to touch a new 52-week low of $0.357. Neuralstem priced its 20 million share offering at $0.40 per share.
Neuralstem, Inc. (NASDAQ:CUR): Check on Earnings
Wall Street will be paying particular attention when Neuralstem, Inc. (NASDAQ:CUR) issues their next quarterly report which is anticipated to go out on or about 2016-05-13 for the period ending on 2016-03-31.
Neuralstem Inc (CUR) Drops 10.71% on April 26
Neuralstem Inc (CUR) was one of the Russell 2000's biggest losers for Tuesday April 26 as the stock slid 10.71% to $0.63, a loss of $-0.075 per share.
Biotech Insights: Analysts Bullish On Novavax, Inc. (NVAX) And Neuralstem, Inc ...
Analysts weigh in on two biotech stocks, Novavax, Inc. (NASDAQ:NVAX) and Neuralstem, Inc. (NASDAQ:CUR) in light of recent events.
Neuralstem Inc (CUR) Jumps 5.56% on April 14
Neuralstem Inc (CUR) was among the biggest gainers on the Russell 2000 for Thursday April 14 as the stock popped 5.56% to $0.78, representing a gain of $0.0409 per share.
Brean Capital Offers Commentary on Neuralstem, Inc. Following Clinical Update ...
Brean Capital's healthcare analyst Jonathan Aschoff came out with a commentary on Neuralstem, Inc. (NASDAQ:CUR), after the company presented an updated analysis of its last completed NSI-566 Phase 1 and 2 trials in ALS at the ANA meeting in Chicago ...
Neuralstem Inc (CUR) Drops 8.26% on April 05
Neuralstem Inc (CUR) was one of the Russell 2000's biggest losers for Tuesday April 05 as the stock slid 8.26% to $0.71, a loss of $-0.0641 per share.